Monoclonal antibodies are one of the most important inventions in modern medicine. They are the workhorse molecules behind cancer immunotherapy, autoimmune drugs, COVID-19 treatments, and a growing number of rare-disease therapies. As of 2026, more than 160 monoclonal antibodies have been approved by the FDA, and dozens more are in late clinical trials.
This guide unpacks what a monoclonal antibody actually is at the molecular level, how they are made, how they work in the body, and why a handful of them changed entire fields of medicine. You can explore approved antibodies interactively in the Antibody Design Lab.
What “monoclonal” actually means
Your immune system produces antibodies all the time. After a vaccine or an infection, B cells generate a polyclonal response — many different antibodies, each binding the target in a slightly different place. That diversity is great for fighting off pathogens, but it is a nightmare for drug manufacturing. You cannot reliably make the same polyclonal mixture twice.
A monoclonal antibody (mAb) solves that problem. Every molecule in a vial of a mAb drug is identical: same heavy chains, same light chains, same binding loops, same target. The word “monoclonal” literally means they all descend from a single ancestral B cell or binder, cloned and produced at scale.
The IgG molecule, briefly
Most therapeutic antibodies are immunoglobulin G (IgG). An IgG looks like the letter Y. The two arms of the Y bind the target — that region is called the Fab. The stem of the Y is called the Fc, and it is the part that talks to the rest of the immune system.
- Heavy chain. Two long protein chains, each about 450 residues, that make up most of the Y.
- Light chain. Two shorter chains, around 220 residues, paired with the heavy chains in the Fab arms.
- Complementarity-determining regions (CDRs). Six short loops at the tips of the Fab arms — three from the heavy chain (CDR-H1, H2, H3) and three from the light chain (CDR-L1, L2, L3). These loops are where almost all of the antibody's binding specificity lives. CDR-H3 is the most variable and usually the most important for affinity.
- Fc region. The constant tail. Different IgG subclasses (IgG1, IgG2, IgG3, IgG4) have different Fc properties and engage immune effector cells differently. Most cancer antibodies are IgG1 because IgG1 drives strong ADCC.
You can see the heavy chain, light chain, and CDR loops of any approved antibody by loading it in the Antibody Design Lab and running an ImmuneBuilder structure prediction.
How monoclonal antibodies are made
Hybridoma technology (1975)
The original method, developed by Köhler and Milstein, fuses a mouse B cell that produces an antibody of interest with a myeloma cell. The fused cell is immortal and keeps cranking out the same antibody forever. Hybridomas earned the 1984 Nobel Prize in Medicine and are still used in some research settings, but the antibodies they produce are mouse, which causes immune reactions in humans.
Chimeric and humanized antibodies (1980s-1990s)
To reduce immunogenicity, researchers grafted the binding loops from a mouse antibody onto a human IgG framework. A chimeric antibody keeps the entire mouse Fab variable domains; a humanized antibody keeps only the CDR loops. Rituximab is chimeric. Trastuzumab is humanized.
Phage display (1990s)
George Smith and Greg Winter shared the 2018 Nobel in Chemistry for phage display, which encodes huge libraries of antibody fragments on the surface of bacteriophages. You wash the library across an immobilized target, recover the phages that stick, and amplify them. Repeat a few rounds and you have an antibody binder — entirely human, no mouse step involved.
Transgenic mice (2000s)
Mice engineered to carry human antibody genes (XenoMouse, HuMAb-Mouse, VelocImmune) generate fully human antibodies when immunized. This is now one of the dominant production routes for new therapeutic mAbs.
How antibodies actually work in the body
1. Direct blockade
The simplest mechanism: the antibody binds a receptor or ligand and physically blocks a signaling event. Pembrolizumab and Nivolumab block PD-1 from talking to PD-L1, releasing the brake on tumor-fighting T cells. Bevacizumab binds VEGF and prevents it from reaching its receptor on blood vessels.
2. Antibody-dependent cellular cytotoxicity (ADCC)
When an IgG1 antibody coats a target cell, NK cells recognize the Fc region through the FcγRIIIa receptor and release perforin and granzymes. The coated cell dies. Trastuzumab and Rituximab both recruit ADCC, and Fc engineering to amplify ADCC has produced more potent next-generation versions like Obinutuzumab.
3. Complement-dependent cytotoxicity (CDC)
Some antibodies activate the complement cascade. C1q binds to the clustered Fc regions on a coated cell, triggers a cascade of proteases, and ultimately punches holes in the target cell membrane. Rituximab is a strong CDC inducer.
4. Payload delivery (antibody-drug conjugates)
Antibody-drug conjugates (ADCs) bolt a small-molecule toxin to the antibody via a chemical linker. The antibody finds the cancer cell, gets internalized, and releases the toxin inside. T-DM1 (Kadcyla) and Trastuzumab deruxtecan (Enhertu) are HER2-targeted ADCs that revolutionized HER2-positive breast cancer treatment.
The drugs that defined the field
A handful of monoclonal antibodies are responsible for an outsized share of clinical and commercial impact:
- Rituximab (1997) — chimeric anti-CD20 antibody for B-cell lymphomas. Proved that monoclonals could be safe, effective, and commercially viable. Still in widespread use.
- Trastuzumab (1998) — humanized anti-HER2 antibody. Transformed HER2-positive breast cancer from a poor-prognosis disease to a treatable one.
- Infliximab and Adalimumab (1998 and 2002) — anti-TNFα antibodies that revolutionized rheumatoid arthritis, Crohn's disease, and psoriasis.
- Bevacizumab (2004) — anti-VEGF antibody, the first practical anti-angiogenic cancer therapy.
- Pembrolizumab and Nivolumab (2014) — anti-PD-1 checkpoint inhibitors that opened the modern era of cancer immunotherapy.
- Dupilumab (2017) — anti-IL-4Rα antibody that unlocked atopic dermatitis, asthma, and a growing list of type-2 inflammatory diseases.
What you can do in the Antibody Design Lab
SciRouter's Antibody Design Lab gives you a hands-on environment for working with antibody sequences and structures:
- Browse approved antibodies (Trastuzumab, Pembrolizumab, Rituximab, and many more) with their heavy and light chain sequences pre-loaded
- Inspect CDR loops and see which residues drive binding specificity
- Run ImmuneBuilder to predict antibody structure from sequence in seconds
- Use AntiFold to design new CDR variants and explore the sequence-function landscape
- Save designs and compare them side by side against the parent antibody
Bottom line
Monoclonal antibodies turned an extremely complicated immune system into something a chemist or biologist can engineer with precision. The combination of single-target specificity, IgG's built-in effector functions, and modern protein engineering has made them the backbone of cancer immunotherapy and a growing share of every other disease area. Understanding their structure and mechanism is the gateway to understanding most of modern biotech.